6492.TWO Senhwa Biosciences, Inc.

Healthcare Biotechnology Taiwan OTC Exchange
29.05 TWD
Close of Nov 6, 2026
27.05 66.50
Market cap
TWD 3.32B
P/E
-
P/B
5.67x
ROE
-48.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6492.TWO undervalued?

Graham number

The Graham number of Senhwa Biosciences, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Senhwa Biosciences, Inc. fundamental analysis

No fundamental analysis for Senhwa Biosciences, Inc. yet.

Senhwa Biosciences, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients. The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II); and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, …

Full company profile